Globus Medical Inc.

Its own filings show it earns most of its revenue at the moment a physical implant is actually used in a procedure, recognized when a consigned product is implanted or title otherwise transfers, rather than when inventory first ships to a hospital. It supplements that with recurring service, maintenance and equipment-leasing income, and its recomputed financial history shows this mix has produced a profit in every year on record rather than an inconsistent or loss-making pattern.

Financial patterns on file describe a company funding its own growth rather than depending on external capital: cash on hand runs well ahead of its debt, cash flow is strong relative to its liabilities, and revenue, profit, free cash flow, book value and receivables have all grown together over multiple years rather than one expanding at another's expense. This describes a financial capacity to scale; CompanyGraph does not separately measure the operational mechanism by which that capacity turns into actual growth.

Its own filings describe reliance on a small number of outside suppliers for many components and materials, including tissue banks that supply the human tissue used in some of its biologic implants, and a limited set of suppliers for parts of its imaging, navigation and robotic systems. CompanyGraph's mapping separately places it with more upstream supply connections than downstream ones, consistent with a position in the middle of a chain that draws on a range of input industries.

Its own filings describe its buyers as hospitals, ambulatory surgery centers and physicians, with government health systems a common counterparty outside the United States. It also states that no single customer accounts for a meaningful share of its revenue, describing a customer base that is broad rather than concentrated in one or a few large buyers.

Its own filings describe what it believes differentiates it: a product-development process built around direct surgeon input and in-house research and testing, fast development cycles, and an internally trained sales force rather than one built solely on outside agents. CompanyGraph cannot confirm that rivals are unable to copy these, and separately notes that the basic kind of business it runs, production bound by long regulatory approval gates, is shared by a distinct, non-trivial number of other companies on file, so that basic shape is not unique to it.

Its own filings describe two relevant contract shapes: some of its imaging, navigation and robotic equipment is placed with hospitals under lease rather than sold outright, and maintenance and support are billed under contracts renewed on a recurring basis rather than per transaction. The filings do not themselves describe this as creating switching costs; CompanyGraph's own reading is that once such equipment is installed in a hospital, replacing it would involve more than a simple purchasing decision, such as removing that equipment and re-contracting service elsewhere, though this is CompanyGraph's interpretation rather than a claim the company makes itself.

Its own filings identify several things that limit how fast it can grow: convincing surgeons and hospitals to adopt its products, securing insurance coverage and reimbursement for procedures that use them, expanding its sales force and distributor network, the available supply of components from its suppliers, and the pace at which regulators clear new products. More broadly, CompanyGraph treats regulatory clearance as the central limiting gate for this kind of medical-device business, a pattern the company's own account is consistent with rather than something CompanyGraph has separately measured for this company.

Its own filings state that the risks it lists first are convincing surgeons and hospitals to adopt its products, pricing pressure from competitors and customers, inadequate insurance coverage and reimbursement, and the risk of being unable to maintain or grow its direct sales and distributor network. It also discloses reliance on a small number of outside suppliers, open patent and contract litigation, and an unresolved regulatory matter over complaint-handling procedures for one of its products.

Its own filings describe a wide regulatory perimeter: national medical-device authorities including the FDA and state licensing bodies oversee it, it reports an open FDA matter over complaint-handling and reporting procedures for one of its navigation products, and it discloses ongoing patent and contract litigation. It also names exposure to export-control and trade-sanctions rules, states that tariff and trade-policy changes could raise input costs or disrupt its supply chain, and identifies currency exposure across a number of foreign markets, some of which it describes as financially unstable or subject to currency controls.